Cytokinetics Inc (NAS:CYTK)
$ 59.23 -0.91 (-1.51%) Market Cap: 6.21 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 41/100

Cytokinetics Inc Discusses Results from FORTITUDE-ALS Transcript

May 06, 2019 / 11:30AM GMT
Release Date Price: $9.48 (+7.12%)
Robert I. Blum
Cytokinetics, Incorporated - CEO, President & Director

Good morning. My name is Robert Blum, and it's my pleasure to welcome you to the Cytokinetics webcast to discuss the results of the FORTITUDE-ALS trial that were announced here yesterday at the American Academy of Neurology Annual Meeting in Philadelphia. This meeting is convening here in Philadelphia but is also being webcast, and we welcome those people who were dialed into the webcast.

Today, we're going to elaborate on some very important data that were presented yesterday at the AAN relating to the development of reldesemtiv for the potential treatment of ALS.

I'll be making and others will be making some forward-looking statements. We will refer you to our SEC filings with regard to caveats to those statements. We do not undertake any obligations to update those statements.

As you know and to set some context, Cytokinetics is a pioneer in developing a new pharmacology relating to modulators of the contractility of muscle, different types of muscle. Today, we're going to be in particular talking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot